We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
Ansell Limited provides health and safety protection solutions. The Company has op...
Ansell Limited provides health and safety prote...
Bringing faster healthier wound healing outcomes to trauma, burn victims and diabe...
Bringing faster healthier wound healing outcome...
We exist to create an alternate future for people living with neurodegenerative di...
We exist to create an alternate future for peop...
Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...
Stoke is pioneering a new way to treat the unde...
We are a clinical stage, publicly traded specialty pharmaceutical company, focused...
We are a clinical stage, publicly traded specia...
Collegium Pharmaceutical is a specialty pharmaceutical company committed to being ...
Collegium Pharmaceutical is a specialty pharmac...
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
Join the National Investor Network and get the latest information with your interests in mind.